Linagliptin is commonly used clinically in the treatment of type 2 diabetes mellitus in an oral form, and it has been shown that the risk of hypoglycemia caused by the DPP4 inhibitor is very low [39]. This evidence concerns the gene DPP4 and Hypoglycemia.